title: Association of kidney transplant failure and antibodies against MICA.
abstract: Despite the progress in renal transplantation, acute rejection and graft failure still occur and chronic rejection continues to be the main problem in long-term allograft survival. Although kidney transplant rejection has been linked to anti-HLA antibodies, not all patients with failed kidney transplants have anti-HLA antibodies, indicating that other loci may be involved. Sera of 63 patients who experienced kidney rejection were compared against sera of 82 patients with functioning transplants. Sera were examined for IgG and IgM anti-HLA Class I and II antibodies. They were also tested by cytotoxicity against panels of 26 endothelial cell lines, 8 MHC class I chain-related gene A (MICA) recombinant cell lines, and 28 B lymphoblast cell lines. Among patients whose transplants failed, 65% had anti-HLA antibodies compared with 45% of those with functioning kidneys (p < 0.05). Similarly, among those whose transplants failed, 41% had anti-endothelial cell antibodies in contrast to 22% in functioning patients (p < 0.05). Among patients whose grafts failed, 52% had anti-MICA antibodies versus 21% of those with functioning grafts (p < 0.001). Eleven patients with failed grafts and 32 with functioning grafts were negative for all of the above. However, 6 of the former and 7 of the latter showed positive cytotoxicity against B lymphoblasts (p < 0.05). Taking all antibodies together, 92% of patients with graft failure had antibodies as opposed to 70% of patients with functioning grafts (p < 0.001). We postulate that antibodies against HLA, MICA, endothelial cells, and B lymphoblasts could be independently involved in the slow process of chronic graft failure.
authors.affiliation: Terasaki Foundation Laboratory, Los Angeles, CA 90064, USA.
authors.forename: Kazuo
authors.initials: K
authors.lastname: Mizutani
authors.forename: Paul
authors.initials: P
authors.lastname: Terasaki
authors.forename: Jean Denis
authors.initials: JD
authors.lastname: Bignon
authors.forename: Maryvonne
authors.initials: M
authors.lastname: Hourmant
authors.forename: Anne
authors.initials: A
authors.lastname: Cesbron-Gautier
authors.forename: Remi N J
authors.initials: RN
authors.lastname: Shih
authors.forename: Rui
authors.initials: R
authors.lastname: Pei
authors.forename: Jarhow
authors.initials: J
authors.lastname: Lee
authors.forename: Miyuki
authors.initials: M
authors.lastname: Ozawa
mesh_terms: D001402:B-Lymphocytes / Q000276:immunology; D002460:Cell Line; D003602:Cytotoxicity, Immunologic; D042783:Endothelial Cells / Q000276:immunology; D005434:Flow Cytometry; D006084:Graft Rejection / Q000097:blood / Q000276:immunology*; D006680:HLA Antigens / Q000276:immunology; D015395:Histocompatibility Antigens Class I / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood*; D007075:Immunoglobulin M / Q000097:blood*; D016030:Kidney Transplantation / Q000276:immunology*; D012189:Retrospective Studies; D013234:Stem Cells / Q000276:immunology
chemical_list: D006680:HLA Antigens; D015395:Histocompatibility Antigens Class I; D007074:Immunoglobulin G; D007075:Immunoglobulin M; C099187:MHC class I-related chain A